A Phase II Study of Abexinostat in Patients with Persistent or Recurrent Follicular Lymphoma


Full Title

Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients with Relapsed or Refractory Follicular Lymphoma


The purpose of this study is to assess the safety and effectiveness of the investigational drug abexinostat in patients with follicular lymphoma that has come back or continued to grow despite prior treatment. Abexinostat blocks a protein called histone deacetylase (HDAC). When HDAC is active, tumors tend to grow, so blocking HDAC could slow tumor growth. Abexinostat is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have grade 1, 2, or 3a follicular lymphoma that continues to grow or came back despite at least three prior regimens of systemic therapy, including chemotherapy and an anti-CD20 antibody (like rituximab).
  • Patients may not have had an allogeneic (donated) stem cell transplant within the last 6 months or autologous (self) stem cell transplant within the 3 months before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Connie Batlevi at 212-639-8081.





Disease Status

Relapsed or Refractory